Literature DB >> 25582324

Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Karidia Diallo1, Du-Ping Zheng, Erin K Rottinghaus, Orji Bassey, Chunfu Yang.   

Abstract

Studying the genetic diversity and natural polymorphisms of HIV-1 would benefit our understanding of HIV drug resistance (HIVDR) development and predict treatment outcomes. In this study, we have characterized the HIV-1 genetic diversity and natural polymorphisms at the 5' region of the pol gene encompassing the protease (PR) and reverse transcriptase (RT) from 271 plasma specimens collected in 2008 from HIV-1-infected patients who were eligible for initiating antiretroviral therapy in Abuja (Nigeria). The analysis indicated that the predominant subtype was subtype G (31.0%), followed by CRF02-AG (19.2 %), CRF43-02G (18.5%), and A/CRF36-cpx (11.4%); the remaining (19.9%) were other subtypes and circulating (CRF) and unique (URF) recombinant forms. Recombinant viruses (68.6%) were the major viral strains in the region. Eighty-four subtype G sequences were further mainly classified into two major and two minor clusters; sequences in the two major clusters were closely related to the HIV-1 strains in two of the three major subtype G clusters detected worldwide. Those in the two minor clusters appear to be new subtype G strains circulating only in Abuja. The pretreatment DR prevalence was <3%; however, numerous natural polymorphisms were present. Eleven polymorphic mutations (G16E, K20I, L23P, E35D, M36I, N37D/S/T, R57K, L63P, and V82I) were detected in the PR that were subtype or CRF specific while only three mutations (D123N, I135T, and I135V) were identified in the RT. Overall, this study indicates an evolving HIV-1 epidemic in Abuja with recombinant viruses becoming the dominant strains and the emergence of new subtype G strains; pretreatment HIVDR was low and the occurrence of natural polymorphism in the PR region was subtype or CRF dependent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582324      PMCID: PMC4696873          DOI: 10.1089/AID.2014.0168

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  71 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

Review 2.  Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

Authors:  Jorge L Martínez-Cajas; Nitika Pant-Pai; Marina B Klein; Mark A Wainberg
Journal:  AIDS Rev       Date:  2008 Oct-Dec       Impact factor: 2.500

3.  HIV infection among pregnant women in Nigeria.

Authors:  A S Sagay; S H Kapiga; G E Imade; J L Sankale; J Idoko; P Kanki
Journal:  Int J Gynaecol Obstet       Date:  2005-07       Impact factor: 3.561

4.  Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.

Authors:  Richard Ugbena; John Aberle-Grasse; Karidia Diallo; Orji Bassey; Tapdiyel Jelpe; Erin Rottinghaus; Aderemi Azeez; Raphael Akpan; Mukhtar Muhammad; Vedapuri Shanmugam; Satvinder Singh; Chunfu Yang
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

5.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

6.  Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria.

Authors:  Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

7.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

8.  Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance.

Authors:  Ana T Dumans; Marcelo A Soares; Elizabeth S Machado; Stéphane Hué; Rodrigo M Brindeiro; Deenan Pillay; Amilcar Tanuri
Journal:  J Infect Dis       Date:  2004-03-12       Impact factor: 5.226

9.  HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations.

Authors:  Joakim Esbjörnsson; Mattias Mild; Fredrik Månsson; Hans Norrgren; Patrik Medstrand
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

10.  Spatiotemporal dynamics of the HIV-1 subtype G epidemic in West and Central Africa.

Authors:  Edson Delatorre; Daiana Mir; Gonzalo Bello
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

View more
  6 in total

Review 1.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

2.  Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria.

Authors:  Mark M Manak; Ogbonnaya S Njoku; Ashley Shutt; Jennifer Malia; Linda L Jagodzinski; Mark Milazzo; Aminu Suleiman; Amos A Ogundeji; Robert Nelson; Ojor R Ayemoba; Robert J O'Connell; Darrell E Singer; Nelson L Michael; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

3.  Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread.

Authors:  Jamirah Nazziwa; Nuno Rodrigues Faria; Beth Chaplin; Holly Rawizza; Phyllis Kanki; Patrick Dakum; Alash'le Abimiku; Man Charurat; Nicaise Ndembi; Joakim Esbjörnsson
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

4.  HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria.

Authors:  Paul E Oluniyi; Fehintola V Ajogbasile; Shuntai Zhou; Iyanuoluwa Fred-Akintunwa; Christina S Polyak; Julie A Ake; Sodsai Tovanabutra; Michael Iroezindu; Morgane Rolland; Christian T Happi
Journal:  AIDS       Date:  2022-01-01       Impact factor: 4.632

5.  Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.

Authors:  Kate El Bouzidi; Rawlings P Datir; Vivian Kwaghe; Sunando Roy; Dan Frampton; Judith Breuer; Obinna Ogbanufe; Fati Murtala-Ibrahim; Man Charurat; Patrick Dakum; Caroline A Sabin; Nicaise Ndembi; Ravindra K Gupta
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.790

6.  Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG.

Authors:  Richard A Heipertz; Ojor Ayemoba; Eric Sanders-Buell; Kultida Poltavee; Phuc Pham; Gustavo H Kijak; Esther Lei; Meera Bose; Shana Howell; Anne Marie OʼSullivan; Adam Bates; Taylor Cervenka; Janelle Kuroiwa; Akindiran Akintunde; Onyekachukwu Ibezim; Abraham Alabi; Obumneke Okoye; Mark Manak; Jennifer Malia; Sheila Peel; Mohammed Maisaka; Darrell Singer; Robert J O'Connell; Merlin L Robb; Jerome H Kim; Nelson L Michael; Ogbonnaya Njoku; Sodsai Tovanabutra
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.